Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

When James E. Golden was diagnosed with prostate cancer he was suddenly faced with the daunting task of interviewing surgeons on “something I know nothing about,” Golden said. Nearly a year later, ...

Modern radiotherapy for prostate cancer is as effective as surgery with important advantages in preservation of urinary ...

A national study of more than 20,000 men with prostate cancer compared long-term outcomes after radiation therapy or surgical removal of the prostate, with follow-up of up to 20 years. Men who ...

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

London specialist clinic Santis Health has received a 2026 Global Recognition Award for combining robotic prostatectomy, real-time pathology and multidisciplinary planning in prostate cancer care.

The optimal strategy for treating newly diagnosed high-risk prostate cancer remains unclear. More specifically, do these patients benefit more from radical prostatectomy or a radiotherapy-based ...

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

Researchers found that MRI was highly accurate in identifying stable cancers, correctly predicting non-progression in 90% to 95% of men with low-risk cancer and 70% of men with intermediate-risk ...

A preliminary study of 52,330 Israeli women found similar rates of heart attack, stroke, blood clots and early death among hormone therapy users and nonusers, though it cannot prove safety. Older ...

Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function. Researchers have found that the use of the NeuroSAFE technique to guide ...